Last reviewed · How we verify
Phosphotope (sodium phosphate (32P))
Phosphotope (generic name: sodium phosphate (32P)) is a drug developed by Mallinckrodt. It is currently FDA-approved (first approved 1959) for Polycythemia vera.
Phosphotope is a small molecule radiopharmaceutical. It is also known by other names, including 32P, Sodium Phosphate (32P), and Sodium Phosphorus (32P) Phosphate.
At a glance
| Generic name | sodium phosphate (32P) |
|---|---|
| Sponsor | Mallinckrodt |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 1959 |
Approved indications
- Polycythemia vera
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phosphotope CI brief — competitive landscape report
- Phosphotope updates RSS · CI watch RSS
- Mallinckrodt portfolio CI
Frequently asked questions about Phosphotope
What is Phosphotope?
What is Phosphotope used for?
Who makes Phosphotope?
What is the generic name of Phosphotope?
When was Phosphotope approved?
What development phase is Phosphotope in?
Related
- Manufacturer: Mallinckrodt — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Polycythemia vera
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing